| Literature DB >> 30682067 |
María Lado-Codesido1, Cristina Méndez Pérez2, Raimundo Mateos3, José Manuel Olivares4, Alejandro García Caballero5,3.
Abstract
INTRODUCTION: Emotion recognition (ER) deficits have been extensively demonstrated in schizophrenia. These deficiencies are not only restricted to facial emotion recognition but also include emotional prosody (tone of the voice) recognition deficits. They have been significantly associated with symptom severity and poor social functioning. The aim of this study was to test the efficacy, in real clinical conditions, of an online self-training prosodic game included in the Social Cognition rehabilitation program e-Motional Training.Entities:
Mesh:
Year: 2019 PMID: 30682067 PMCID: PMC6347191 DOI: 10.1371/journal.pone.0210816
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1CONSORT flowchart.
Fig 2Sessions for Voices.
Reprinted from www.e-motionaltraining.com under a CC BY license, with permission from Fundación Biomédica Galicia Sur, original copyright 2018.
Fig 3Voices program.
Reprinted from www.e-motionaltraining.com under a CC BY license, with permission from Fundación Biomédica Galicia Sur, original copyright 2018.
Characteristics of the training sessions.
| Training session | Number of fragments | Number of response options | Observations |
|---|---|---|---|
| 20 | 2 | Simple dichotomous emotions (happiness/sadness, anger/fear, disgust/neutral) | |
| 20 | 2 and 3 | Simple and complex emotions | |
| 20 | 3 | Complex emotions | |
| 20 | 3 and 4 | Complex emotions | |
| 20 | 4 | Complex emotions | |
| 45 | 2, 3 and 4 | Simple and complex emotions |
Sample size Calculation I.
| Expected standard deviation | |
|---|---|
| Population A | 3210 |
| Population B | 2410 |
| Expected difference of means | 3690 |
| Ratio between samples (B/A) | 1000 |
| Confidence level | 95.0% |
Sample size Calculation II.
| Power, % | Sample size | |
|---|---|---|
| Population A | Population B | |
| 95.0 | 16 | 16 |
| 96.0 | 17 | 17 |
| 97.0 | 18 | 18 |
| 98.0 | 20 | 20 |
| 99.0 | 22 | 22 |
Sample description.
| Demographic characteristic | Percentage |
|---|---|
| Sex | Male: 52% |
| Female: 48% | |
| Age, years (SD) | 40.9 (12.1) |
| Occupation | Active: 6% |
| Inactive: 88% | |
| Students: 4% | |
| Marginal activities: 2% | |
| Education level | Without primary studies: 8% |
| Primary studies: 22% | |
| Secondary studies: 62% | |
| University studies: 4% | |
| Unknown: 4% | |
| Marital status | Single: 84% |
| Married: 6% | |
| Widowed: 2% | |
| Separated: 8% | |
| Familiar coexistence | Alone: 8% |
| With parents: 54% | |
| As a couple: 8% | |
| Siblings: 2% | |
| Others: 28% | |
| Diagnosis | Schizophrenia: 90% |
| Schizoaffective disorder: 10% | |
| Associated Diagnosis | No other diagnosis: 76% |
| Substance-related and addictive disorder (in the past): 10% | |
| Mood disorders: 2% | |
| Somatic symptom and related disorders: 2% | |
| Personality disorders: 8% | |
| Neurodevelopmental disorders: 2% | |
| Equivalence to chlorpromazine, mg (SD) | 1008.30 (652.75) |
| Oral treatment, mg. | 632.61 (548.17) |
| Injectable treatment, mg. | 972.00 (476.50) |
| Benzodiazepines | Yes: 44% |
| No: 56% | |
| Antidepressants | Yes: 52% |
| No: 48% | |
| Mood stabilizers | Yes: 18% |
| No: 82% |
Demographic and clinical characteristics by subgroups.
means and standard deviations are presented for continuous variables.
| VARIABLE | GROUP | p-value | ||
|---|---|---|---|---|
| INTERVENTION (n = 26) | CONTROL | |||
| Male | 13 | 13 | 0.768 | |
| Female | 13 | 11 | ||
| 40.7 (12.22) | 41.2 (12.14) | 0.969 | ||
| Single | 23 | 19 | 0.451 | |
| Married | 2 | 1 | ||
| Widowed | 0 | 1 | ||
| Separated | 1 | 3 | ||
| Alone | 2 | 2 | 0.717 | |
| As a couple | 2 | 2 | ||
| With family | 15 | 13 | ||
| Others | 5 | 9 | ||
| Active | 1 | 2 | 0.341 | |
| Inactive | 23 | 21 | ||
| Student | 2 | 0 | ||
| Marginal Activities | 0 | 1 | ||
| No studies | 1 | 3 | 0.362 | |
| Primary | 8 | 3 | ||
| Secondary | 16 | 15 | ||
| University | 0 | 2 | ||
| Unknown | 1 | 1 | ||
| Schizophrenia | 24 | 21 | 0.461 | |
| Schizoaffective disorder | 2 | 3 | ||
| Antipsychotics | 26 | 24 | ||
| Benzodiazepines | 11 | 11 | 0.802 | |
| Mood stabilizers | 3 | 6 | 0.193 | |
| Antidepressants | 15 | 11 | 0.402 | |
| 921.7 | 1102 | 0.334 | ||
| (578.7) | (725.3) | |||
| PANSS-P | 11.8(4.8) | 14.0(6.8) | 0.194 | |
| PANSS-N | 22.6(7.8) | 20.9 (8.6) | 0.485 | |
| PANSS-C | -11.0(6.8) | -7.0(9.0) | 0.084 | |
| PANSS-T | 52.3(18.2) | 56.7(19.3) | 0.411 | |
| 98.8(31.6) | 96.9 (33.5) | 0.838 | ||
| 20.(4.1) | 20.1(4.2) | 0.944 | ||
Abbreviations: CPZ, chlorpromazine; K-BIT, Kauffman Brief Intelligence Test; PANSS, Positive and Negative Syndrome Scale; RMV-SV, Reading the Mind in the Voice—Spanish version; in brackets, SD.
Linear regression analysis.
| RMV-SV | Control | Intervention | β | p-value | ||
|---|---|---|---|---|---|---|
| Pre | post | pre | Post | |||
| Mean | 20.08 | 19.25 | 20.00 | 22.92 | 3,6 | <0,001 |
| SD | 4.23 | 4.93 | 4.08 | 4.43 | ||
| Median | 20.50 | 18.50 | 20.00 | 24.00 | ||
| Min. | 11.0 | 6.0 | 12.0 | 11.0 | ||
| Max. | 28.0 | 29.0 | 28.0 | 29.0 | ||
Abbreviations: β: Regression coefficient for the study group.
Fig 4RMV-SV results for both control and intervention group.
The left part of the figure represents RMV-SV scores of the control group and the right part represents the RMV-SV scores of the intervention group. The red and green boxes contain the fifty per cent of the results of the RMV-SV scores pre and post-intervention in the different groups. Whiskers indicate the extreme scores of the RMV-SV test.
RMV-SV values before and after the voices rehabilitation.
| GROUP | RMV-SV pre | RMV-SV post | |
|---|---|---|---|
| Control | Mean | 20.08 | 19.25 |
| Standard deviation | 4.23 | 4.93 | |
| Median | 20.50 | 18.50 | |
| Min. | 11.0 | 6.0 | |
| Max. | 28.0 | 29.0 | |
| Intervention | Mean | 20.00 | 22.92 |
| Standard deviation | 4.08 | 4.43 | |
| Median | 20.00 | 24.00 | |
| Min. | 12.0 | 11.0 | |
| Max. | 28.0 | 29.0 | |
| p-value | 0.944 | 0.009 |
Abbreviations: RMV-SV, Reading the Mind in the Voice—Spanish version.
Fig 5Users’ evaluation of voices.